Cindy Tahl Sells 8,091 Shares of Fate Therapeutics, Inc. (FATE) Stock

Fate Therapeutics, Inc. (NASDAQ:FATE) General Counsel Cindy Tahl sold 8,091 shares of Fate Therapeutics stock in a transaction on Monday, October 16th. The shares were sold at an average price of $3.85, for a total value of $31,150.35. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Fate Therapeutics, Inc. (NASDAQ FATE) traded up 6.78% on Thursday, hitting $4.25. The stock had a trading volume of 320,509 shares. The company has a 50-day moving average price of $4.13 and a 200 day moving average price of $3.66. The firm’s market cap is $176.01 million. Fate Therapeutics, Inc. has a 52-week low of $1.80 and a 52-week high of $5.68.

Fate Therapeutics (NASDAQ:FATE) last issued its earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.01. The company had revenue of $1.03 million during the quarter, compared to analyst estimates of $1.02 million. Fate Therapeutics had a negative return on equity of 67.01% and a negative net margin of 887.68%. Equities analysts forecast that Fate Therapeutics, Inc. will post ($0.97) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2017/10/26/cindy-tahl-sells-8091-shares-of-fate-therapeutics-inc-fate-stock.html.

A number of brokerages have issued reports on FATE. Zacks Investment Research cut Fate Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, September 6th. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Fate Therapeutics in a research note on Thursday, October 12th. Leerink Swann restated an “outperform” rating and issued a $7.00 price target on shares of Fate Therapeutics in a research note on Friday, September 8th. Finally, ValuEngine cut Fate Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, August 7th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $6.79.

Hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN raised its stake in Fate Therapeutics by 926.7% in the 1st quarter. Wells Fargo & Company MN now owns 281,111 shares of the biopharmaceutical company’s stock worth $1,279,000 after acquiring an additional 253,732 shares during the last quarter. Morgan Stanley raised its stake in Fate Therapeutics by 9.8% in the 1st quarter. Morgan Stanley now owns 611,646 shares of the biopharmaceutical company’s stock worth $2,783,000 after acquiring an additional 54,615 shares during the last quarter. Neuberger Berman Group LLC purchased a new position in Fate Therapeutics in the 1st quarter worth $312,000. Driehaus Capital Management LLC purchased a new position in shares of Fate Therapeutics during the 1st quarter valued at about $145,000. Finally, KCG Holdings Inc. raised its stake in shares of Fate Therapeutics by 7.8% during the 1st quarter. KCG Holdings Inc. now owns 24,480 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 1,764 shares during the last quarter. Institutional investors own 64.27% of the company’s stock.

About Fate Therapeutics

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Receive News & Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply